Cardiac Remodeling
8
0
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition
Baxdrostat and Ventricular Remodeling
AI-ECG for Time-Resolved Prediction of HFrEF
Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction
Post-Myocardial Infarction Remodeling Prevention Therapy
Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis